Thermo Fisher Q3 revenue rises 9% to $12.14 billion

WALTHAM, Mass., Oct. 21. Thermo Fisher Scientific Inc. (NYSE: TMO) reported third quarter 2026 revenue of $12.14 billion, an increase of 9% from the same period in 2025. The company stated that organic revenue growth was 6% for the quarter ended September 26, 2026.

GAAP diluted earnings per share (EPS) rose 9% to $4.64, while adjusted EPS grew 15% to $6.68. GAAP operating income for the quarter was $2.26 billion, a 17% increase over the year-ago period, resulting in a GAAP operating margin of 18.6%, up from 17.4% in the third quarter of 2025. Adjusted operating income reached $2.97 billion, a 15% year-over-year increase, with an adjusted operating margin of 24.5%, compared to 23.3% in the prior year's third quarter.

Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific, attributed the performance to the company's growth strategy and its PPI Business System. He stated that the strategy is resonating with customers and enabling execution across the organization. Casper added that the company is positioned to deliver results for the full year 2026 while continuing to build long-term value for stakeholders.

During the quarter, Thermo Fisher launched several new products and initiatives. The company introduced the Thermo Scientific Orbitrap Isora mass spectrometer, described as the first Orbitrap system designed for isotope ratio analysis to support environmental and life sciences research. It also released the Thermo Scientific EMPAD G2 electron detector for electron microscopy characterization of advanced materials. In diagnostics, the FDA-cleared EliA CTD 13 Screen became available in the United States as a new autoimmune test for systemic connective tissue diseases, including lupus. Additionally, the Ion 560 Chip was launched for the Ion GeneStudio S5 platform, offering nearly twice the sequencing capacity of the previous offering to support genomic profiling in oncology research.

The company expanded its partnerships and infrastructure. Thermo Fisher launched Precure in partnership with Mayo Clinic, an initiative combining data from more than one million patient samples with proteomics technologies including Orbitrap mass spectrometry and Olink to advance precision medicine. In South Korea, the company opened its first AI-Automation Innovation Center to integrate analytical technologies, automation, and AI. A new automated distribution center opened in Kentucky to improve supply speed and flexibility for North American customers.

Thermo Fisher completed the divestiture of its microbiology business during the quarter as part of its capital deployment strategy. The company plans to provide updated financial guidance for 2026 during its earnings conference call scheduled for October 21, 2026, at 7:00 a.m. Eastern Time. The call will be webcast live on the company's website and can be accessed by dialing (833) 461-5787 within the U.S. or +1 (585) 542-9983 outside the U.S., using access code 500554659.